Type 2 diabetes is characterized by impaired β-cell function associated with a reduction of insulin secretion and β-cell mass. Empagliflozin is a specific sodium glucose cotransporter type-2 (SGLT-2) inhibitor that may provide longer efficacy compared to available treatments. This study compared the durability of empagliflozin treatment against glibenclamide and liraglutide in diabetic rats. Empagliflozin and liraglutide led to marked improvements in fed glucose and hemoglobin A1c levels, as well as impeding a decline in insulin levels. Glibenclamide was ineffective. The effects of liraglutide were less pronounced at week 8 of treatment compared to week 4, whereas those of empagliflozin remained stable throughout the study period. Similarly, empagliflozin improved glucose tolerance and preserved insulin secretion. These effects were reflected by less reduction in β-cell mass. In comparison to other type 2 diabetic treatments, SGLT-2 inhibitors may enhance durability of efficacy through insulin-independent pathways.
See article at J Pharmacol Exp Ther 2014, 350:657–664.
- Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics